Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Non-clinical in vitro evaluation of antibiotic resistance gene-free plasmids encoding human or murine IL-12 intended for first-in-human clinical study
Authors:ID Kos, Špela (Author)
ID Omerzel, Maša (Author)
ID Jesenko, Tanja (Author)
ID Markelc, Boštjan (Author)
ID Kamenšek, Urška (Author)
ID Žnidar, Katarina (Author)
ID Matkovič, Urška (Author)
ID Renčelj, Andrej (Author)
ID Serša, Gregor (Author)
ID Hudej, Rosana (Author)
ID Tuljak, Aneja (Author)
ID Peterka, Matjaž (Author)
ID Čemažar, Maja (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/1999-4923/13/10/1739
 
.pdf PDF - Presentation file, download (4,73 MB)
MD5: 87878D46C53DE309B86F5F56CCD619CC
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Interleukin 12 (IL-12) is a key cytokine that mediates antitumor activity of immune cells. To fulfill its clinical potential, the development is focused on localized delivery systems, such as gene electrotransfer, which can provide localized delivery of IL-12 to the tumor microenvironment. Gene electrotransfer of the plasmid encoding human IL-12 is already in clinical trials in USA, demonstrating positive results in the treatment of melanoma patients. To comply with EU regulatory requirements for clinical application, which recommend the use of antibiotic resistance gene-free plasmids, we constructed and developed the production process for the clinical grade quality antibiotic resistance gene-free plasmid encoding human IL-12 (p21-hIL-12-ORT) and its ortholog encoding murine IL-12 (p21-mIL-12-ORT). To demonstrate the suitability of the p21-hIL-12-ORT or p21-mIL-12-ORT plasmid for the first-in-human clinical trial, the biological activity of the expressed transgene, its level of expression and plasmid copy number were determined in vitro in the human squamous cell carcinoma cell line FaDu and the murine colon carcinoma cell line CT26. The results of the non-clinical evaluation in vitro set the basis for further in vivo testing and evaluation of antitumor activity of therapeutic molecules in murine models as well as provide crucial data for further clinical trials of the constructed antibiotic resistance gene-free plasmid in humans.
Keywords:interleukin 12, gene electrotransfer, antibiotic resistance, plasmids
Publication status:Published
Publication version:Version of Record
Publication date:19.10.2021
Place of publishing:Basel
Publisher:MDPI AG
Year of publishing:2021
Number of pages:str. 1-1739-22-1739
Numbering:Vol. 13
PID:20.500.12556/DiRROS-15456 New window
UDC:602.6/.7
ISSN on article:1999-4923
DOI:10.3390/pharmaceutics13101739 New window
COBISS.SI-ID:81662723 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 20. 10. 2021;
Publication date in DiRROS:07.09.2022
Views:491
Downloads:292
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Pharmaceutics
Shortened title:Pharmaceutics
Publisher:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003-2015
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARRS - Slovenian Research Agency
Project number:J3-2528-2020
Name:Imunski genski elektroprenos IL-12 in IL-2 za zdravljenje immunološko hladnih/vročih tumorjih

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:07.09.2022

Secondary language

Language:Slovenian
Keywords:interlevkin 12, genski elektroprenos, odpornost na antibiotike, plazmidi


Back